For Healthcare Professionals

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer


About the study

This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Key Inclusion Criteria:

  1. Patients with histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).
  2. Patients must undergo radical surgery.
  3. No prior anti-cancer therapy for the current malignancy.
  4. World Health Organization (WHO)/ECOG performance status of 0 or 1 at enrollment.
  5. Adequate organ and marrow function.
  6. Availability of tumor sample prior to study entry.
  7. Must have a life expectancy of at least 24 weeks.


Key Exclusion Criteria:

  1. Patients with peritoneal dissemination or distant metastasis.
  2. Patients with adenosquamous cell carcinoma, squamous cell carcinoma, or GI stromal tumor.
  3. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.
  4. Contra-indication to any of the study drugs.
  5. History of allogeneic organ transplantation.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Gastrointestinal Neoplasms,Esophagogastric Junction

Age (in years)

18 - 200


Phase 3

Participants needed


Est. Completion Date

Feb 14, 2025

Treatment type



AstraZeneca identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.